chartexchange

PVCT
PROVECTUS BIOPHARMS
stockOTC

EODNov 18, 2026
0.0437USD-0.046%(-0.00)61,190
Loading…
Loading…
Healthcare
Biotechnology
HQ
Knoxville, TN, USA
Previous Close
$0.04
Beta
-0.19
52-Week High
$0.08 2026-07-09
52-Week Low
$0.04 2026-11-12
SMA 50
$0.05
SMA 200
$0.06
Avg. Vol 10D
282,693
Avg. Vol 30D
144,336
Avg. Vol 90D
139,850
Relative Vol
0.42
419.91M
389.33M
4,423
Apr 11, 2002 · 1-for-300.3003 (reverse)
PVCT Profile

provectus biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. provectus' investigational oncology drug, pv-10, is an ablative immunotherapy under investigation in solid tumor cancers.

PVCT Performance
PeriodPriceDateChangeBeta
1W0.042026-11-12+2.82%-4.287
1M0.052026-10-19-10.63%-1.317
3M0.062026-08-19-24.91%-0.354
6M0.072026-05-19-33.85%-0.675
1Y0.072025-11-19-37.35%-0.190
2Y0.112024-11-19-60.29%—
5Y0.052021-11-19-13.46%-0.060
PVCT Stock Summary

PROVECTUS BIOPHARMS (OTC:PVCT) stock price today is $0.04, and today's volume is 61,190. PVCT is down 0.046% today. The 30 day average volume is 144,336. PVCT market cap is $18.35M with 419.91M shares outstanding.